VBL Therapeutics Announces Additional New European Patent
VBL Therapeutics recently announced the European Patent Office (EPO) has granted Patent No. 3328401, which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat oncology conditions.
VBL has identified MOSPD2 as a novel target whose expression is induced in multiple tumors, including colon, esophagus, liver, and breast among others. Expression of MOSPD2 plays a role in the ability of cancer cells to metastasize. The point that MOSPD2 is expressed abundantly and specifically on tumors, but not on normal tissues, makes it a good and novel target for killing of tumor cells.
“This new patent is an important milestone achieved by VBL in securing intellectual property protection for our MOSPD2 program and for targeting MOSPD2 for anti-cancer therapy,“ said Erez Feige, PhD, MBA, VP Business Operations at VBL. Previously, VBL announced the grant of another European Patent No. 3328408, which covers VBL’s proprietary antibodies to treat inflammatory conditions.
The claims in the granted patent cover the use of such anti-MOSPD2 antibody/antibody fragment to treat a wide range of cancers which express MOSPD2, including solid tumors and hematological cancers. The patent is expected to provide protection for VBL’s anti-MOSPD2 platform, until at least July 2036.
VBL is conducting two parallel drug development programs that are exploring the potential of MOSPD2 (motile sperm domain-containing protein 2), a protein that VBL has identified as a key regulator of cell motility, as a therapeutic target for inflammatory diseases and cancer. The company’s VB-600 platform comprises classical anti-MOSPD2 monoclonal antibody candidates for inflammatory indications, as well as bi-specific antibody candidates for oncology.
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every 6-8 weeks. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in a VBL-sponsored “all comers” Phase 1 trial as well as in three VBL-sponsored tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a VBL-sponsored Phase 3 potential registration trial for platinum-resistant ovarian cancer.
Total Page Views: 940
